Phase I Study of Decitabine (Dacogen) and Bortezomib (Velcade) in Acute Myeloid Leukemia.
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2014
At a glance
- Drugs Bortezomib (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 18 Jul 2012 Planned end date changed from 1 Jan 2009 to 1 Jan 2100 as reported by ClinicalTrials.gov.
- 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.